Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06161025 · ClinicalTrials.gov registry record · Phase 2
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Phase 2 study of Solid Cancer, sponsored by Daiichi Sankyo.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 860
- Enrollment target
- 20
- Study locations
NCT06161025: Recruiting Phase 2 study of Solid Cancer, sponsored by Daiichi Sankyo.
NCT06161025 is a Phase 2 study of Solid Cancer that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 860 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (547% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06161025, a Phase 2 study of Solid Cancer, is actively recruiting participants, sponsored by Daiichi Sankyo.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 860 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.
Primary Outcome
The ORR was defined as the percentage of participants with confirmed Complete Response (CR) or Partial Response (PR), by BICR assessment based on RECIST version 1.1.
Conditions Studied
Interventions
- DRUG Paclitaxel
- DRUG Topotecan
- DRUG R-DXd
- DRUG PLD
Study Locations (20)
Florida
- Sylvester Comprehensive Cancer Center at Lennar - Coral Gables
- Sylvester Comprehensive Cancer Center at Deerfield Beach - Deerfield Beach
- Florida Cancer Specialists - Lake Mary
- Sylvester Cancer Center - Miami
- Mount Sinai Comprehensive Cancer Center - Miami Beach
- Sylvester Comprehensive Cancer Center at Plantation - Plantation
New York
- NHPP Imbert - Bay Shore
- Northwell Health, LLC PRIME - Lake Success
- Perlmutter Cancer Center at NYU Langone Hospital- Long Island - Mineola
- NYU Langone Health - New York
- NHPP LHH - New York
Indiana
- Community MD Anderson Cancer Center- East - Indianapolis
- Community MD Anderson Cancer Center- South - Indianapolis
- Community Health Network - MD Anderson - Indianapolis
New Jersey
- Valley Health System - Paramus
- Holy Name - Teaneck
Alaska
- Alaska Women's Cancer Care - Anchorage
Connecticut
- Yale University School of Medicine - New Haven
Kentucky
- St. Elizabeth Medical Center - Edgewood
Missouri
- Washington University School of Medicine Obstetrics and Gynecology - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 860 participants |
| Start Date | 2024-02-27 |
| Est. Completion | 2030-04-30 |
| Phase | Phase 2 |
What NCT06161025 shows while recruiting
NCT06161025 is an interventional study that assigns participants to a tested intervention. The registered 860 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (547% higher).
The record links to 1 condition, with Solid Cancer appearing as the primary indexed condition, and to 4 interventions - of which Paclitaxel is the first listed.
NCT06161025 names 20 study sites across 8 states, led by Florida, New York, Indiana.
Frequently Asked Questions
What is clinical trial NCT06161025 about?
NCT06161025 is a clinical study titled "A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer". This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.
What is the current status of trial NCT06161025?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 860 participants. The study started on 2024-02-27. Estimated completion is 2030-04-30.
What conditions does trial NCT06161025 study?
This clinical trial studies the following conditions: Solid Cancer.
What interventions are being tested in trial NCT06161025?
The interventions under investigation include: Paclitaxel (DRUG), Topotecan (DRUG), R-DXd (DRUG), PLD (DRUG).
Who is sponsoring clinical trial NCT06161025?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06161025 being conducted?
This trial has 20 study locations across Alaska, Connecticut, Florida, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06161025's enrollment target sits among peer trials
860 33rd of 2000 higher than 1,967 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04541381 · 860 participants · NA
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
- NCT05211895 · 860 participants · Phase 3
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
- NCT06541574 · 860 participants · Phase 2
Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial
- NCT07410117 · 860 participants · Phase 3
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI